clinical trial · NCT06691984
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Amgen·phase3·recruiting·n = 675
Metastatic Castration-resistant Prostate CancerXaluritamigAbirateroneEnzalutamideCabazitaxel
brief summary
The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy \[ARDT\]).
started
Dec 9, 2024
primary completion
Jan 2, 2029
completion
Jul 30, 2029
last updated
Mar 6, 2026
official title
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol